AUA 2026: Previewing Metastatic Prostate Cancer Updates Hannah D. McManus, MD May 06, 2026

https://www.medscape.com/viewarticle/mdangle-aua-2026-metastatic-prostate-cancer-preview-2026a1000amf Hannah D. McManus, MD, describes the upcoming American Urological Association meeting as a key forum for multidisciplinary collaboration in treating metastatic prostate cancer. She is particularly looking forward to new data from major phase 3 trials, including prostate-specific antigen endpoints from the PSMAddition trial, which is studying lutetium PSMA-617 in the metastatic hormone-sensitive setting. Additional anticipated presentations include radiographic progression-free survival data from the TALAPRO-2 study of talazoparib, safety data from the TRITON3 trial of rucaparib, and relevant findings from the EMBARK study on enzalutamide in high-risk biochemical recurrent disease.